In short. Nevus of Ota is a one-sided blue-grey birthmark following the upper branches of the trigeminal nerve across the cheek, temple and eyelid. Its colour comes from melanocytes resting deep in the dermis, so it reads slate-blue rather than brown, responds to pigment-targeting lasers, and needs a baseline eye examination when the eyelid or sclera is involved.
Key points
- Blue-grey colour comes from deep dermal pigment and the way light scatters.
- Roughly half are present at birth; the rest appear during adolescence or pregnancy.
- Q-switched and picosecond lasers are the mainstay, with sessions spaced weeks to months apart.
- Complete clearance is not guaranteed, and is less likely with dark, extensive or eye-involving marks.
- Darker skin carries a higher risk of post-inflammatory hyperpigmentation after laser treatment.
A birthmark in the upper trigeminal distribution
Nevus of Ota presents as blue-grey to brownish patches on one side of the face, following the distribution of the upper branches of the trigeminal nerve: typically the cheek, the temple, the eyelid, and the area around the eye. It is present at birth in roughly half of cases and appears during adolescence or pregnancy in the rest. It is considerably more common in Asian and darker-skinned populations, and it affects women more often than men.
The colour comes from depth
The cause is developmental. Melanocytes that should have migrated out of the dermis during early development remain there. Because that pigment sits deep in the skin, light passing through the surface scatters and returns mostly blue, the same optical effect that makes a vein look blue through skin. This is why the mark reads as slate-blue or grey-blue rather than brown, and why the depth matters for treatment.
What happens at assessment?
The diagnosis is usually made by looking. A dermatologist examines the distribution, uses dermoscopy to confirm the deep pigment, and checks the eye. In some people the sclera, the white of the eye, carries pigment too, and that is a reason for a baseline ophthalmology examination, because a minority of patients develop raised pressure inside the eye. Neurological examination is warranted if the distribution is unusual or if there are other symptoms.
Why is earlier assessment worthwhile?
Nevus of Ota responds to pigment-targeting lasers, and it generally responds better in younger skin and earlier in the condition's history, before the pigment has had decades to settle. That is a general pattern rather than a guarantee, and it has to be weighed against the risks of treating children. The practical consequence is that assessment early is worthwhile even if treatment is deferred.
What does pigment-targeting laser treatment involve?
Pigment-specific laser systems, Q-switched and picosecond devices that target melanin, are the mainstay of treatment. Most people need multiple sessions spaced weeks to months apart, and the sessions are cumulative: each one removes a proportion of the pigment. Results are often good, and lightening is the usual outcome. Complete clearance is not guaranteed, and it is less likely when the mark is very dark, very extensive, or involves the eye.
| What it can do | What it cannot do | |
|---|---|---|
| Colour | Lighten the blue-grey patch | Guarantee complete clearance |
| Sessions | Remove a proportion of pigment with each session | Typically avoid multiple sessions spaced weeks to months apart |
| Timing | Respond better in younger skin and earlier in the condition's history | Make that pattern a guarantee |
| Dark, extensive marks | Be attempted with conservative settings and a test spot | Clear as reliably as smaller, lighter marks |
| Eye involvement | Treat skin around the eyelid | Remove scleral pigment, which is monitored instead |
| Recurrence | Maintain lightening in the short term | Prevent partial recurrence over years |
What are the limits and risks?
Risks are real and have to be part of the decision. Darker skin types are more prone to post-inflammatory hyperpigmentation after treatment; hypopigmentation, textural change, and scarring can occur; and partial recurrence over years is well recognised. A test spot, conservative settings, and a planned interval are what make treatment safe rather than merely aggressive.
Before any treatment of a facial birthmark
- Confirm the diagnosis, because a blue-grey patch can be a different dermal melanocytosis or a mole with deep pigment.
- Have a baseline eye examination if the eyelid or the white of the eye is involved.
- Ask about test spots, expected number of sessions, and what happens if pigment returns; results are partial and revision is often needed.
Sources
- American Academy of Dermatology — pigmented birthmarks
- British Association of Dermatologists — laser and light therapy for skin lesions patient information
- Chinese Medical Association Dermatology Branch — clinical guidance on pigmentary disorders
Internal links
Frequently asked questions
Why does nevus of Ota look blue rather than brown?
Melanocytes that should have migrated out of the dermis during early development remain there. Light passing through the skin surface scatters and returns mostly blue, the same optical effect that makes a vein look blue through skin. That depth also shapes treatment.
Does nevus of Ota need an eye examination?
Yes, if the eyelid or the white of the eye is involved. A baseline ophthalmology examination is arranged because a minority of patients develop raised pressure inside the eye, and the sclera itself can carry pigment that is monitored rather than lasered.
Can laser treatment clear nevus of Ota completely?
Complete clearance is not guaranteed and is less likely when the mark is very dark, very extensive, or involves the eye. Most people need multiple sessions spaced weeks to months apart, with cumulative and often partial lightening. Partial recurrence over years is well recognised.
Risks & Limitations
- Most chronic skin disease is managed rather than cured, and relapse is expected.
- Treatments typically need 8–12 weeks before response can be judged fairly.
- Topical treatment can cause irritation, dryness, peeling and photosensitivity.
- Systemic therapy may require blood monitoring and carries organ, metabolic and pregnancy risks.
- Isotretinoin in particular requires strict monitoring and pregnancy prevention.
- Pigment change is often slow and may be incomplete.
- No treatment works for everyone, and response cannot be predicted with certainty.
When to Seek Care
- A mole or lesion that changes in size, shape or colour, or starts to bleed, itch or crust.
- Fever with a widespread rash, blistering, or rash involving the eyes, mouth or genitals — seek emergency care.
- Rapidly spreading redness, swelling or pain in the skin.
- Facial swelling or difficulty breathing — possible severe reaction; seek emergency care immediately.
- New or worsening symptoms while taking a monitored medication.
References & Further Reading
- American Academy of Dermatology (AAD) — public and clinical guidance
- World Health Organization (WHO) — skin and infectious disease resources
- Chinese Medical Association, Dermatology Branch — clinical guidance
- Cochrane Library — systematic reviews in dermatology
This page is patient education, not medical advice, and it does not cite individual studies. Discuss your own case with a qualified clinician. To arrange an assessment at Chongqing West District Hospital, see Contact & Consultation.